Results

Mitsubishi Tanabe Pharma Corporation

07/27/2018 | Press release | Distributed by Public on 07/26/2018 20:03

Mitsubishi Tanabe Pharma's MT-7117 Receives U.S. FDA Fast Track Designation for the Investigational Treatment of Patients with the Ultra-Rare Disease, Erythropoietic Protoporphyria